Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDE | P14735 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 1/20 | 0.53 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.49 |
| ▸ | HTR3B | O95264 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422976 | 0.85 | PDGFRB (0.55) | IDEMEN1KMT2APDGFRBAKT1 | |
| SCHEMBL30060970 | 0.85 | PDGFRB (0.57) | IDESMN1; SMN2MEN1KMT2APDGFRB | |
| SCHEMBL14515648 | 0.83 | CLK1 (0.68) | IDESMN1; SMN2MEN1KMT2APDGFRB | |
| SCHEMBL6186988 | 0.82 | MAPT (0.57) | IDESMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL27486036 | 0.82 | IDE (0.53) | IDESMN1; SMN2GAAHTTMEN1 | |
| SCHEMBL899673 | 0.81 | IDE (0.49) | IDESMN1; SMN2MEN1KMT2APDGFRB | |
| SCHEMBL20274129 | 0.81 | CCR5 (0.57) | IDESMN1; SMN2MEN1KMT2APDGFRB | |
| SCHEMBL19422866 | 0.79 | AKT1 (0.58) | IDEMEN1KMT2APDGFRBAKT1 | |
| SCHEMBL5369080 | 0.77 | POLB (0.54) | IDEMEN1KMT2APDGFRBPOLB | |
| SCHEMBL30572691 | 0.77 | MEN1 (0.57) | IDESMN1; SMN2GAAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621923-B1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INT BV (NL) | 2017-03-29 | — | — | EP | disclosed |
| US-8883791-B2 | N-heteroaryl compounds with cyclic bridging unit for the treatment of parasitic diseases | INTERVET INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INC. | 2013-08-08 | — | — | US | disclosed |
| EP-2621923-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | Intervet International B.V. (NL) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012041872-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | INTERVET INTERNATIONAL B.V. (NL) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203768-A1 | N-HETEROARYL COMPOUNDS WITH CYCLIC BRIDGING UNIT FOR THE TREATMENT OF PARASITIC DISEASES | PIGO, HNMT, PIGS | IDE 1067/4885SMN1; SMN2 3476/4885GAA 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.